DOCSLIB.ORG

NYC Healthcare Venture Capital Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NYC Healthcare Venture Capital Report 2020 New York City Healthcare Venture Capital Report INTRODUCTION Welcome to the third annual New York City Healthcare Venture Capital Report. 2019 marked the ten-year anniversary of NYC Health We also explore key trends that are driving investment, Business Leaders (NYCHBL), during which we have seen interest and excitement including: a decade of incredible growth for NYC health start-ups. When Dr. Yin Ho and I co-founded NYCHBL in 2009, • LIFE SCIENCES. A decade ago, it was hard to name our goal was to build an organization that would help any biotechs calling NYC home. Today it’s a vastly connect people passionate about healthcare, because different story as you’ll learn from our dedicated section we believed that NYC should be at the center of on the sector’s growth. (See pages 16-19) healthcare innovation given our many assets. Ten years, • DIGITAL THERAPEUTICS. An emerging area that 55 events and 250 speakers later, New York City has in marries therapeutics with technology to drive better fact become the epicenter of tech-driven healthcare. It’s patient outcomes, digital therapeutics (DTx) are gaining rewarding that we’ve been able to play a part in the traction. As we hear from leaders in this exciting growth story. space, DTx are poised to change clinical practice The 2020 report reflects your overwhelming response, and alter the way healthcare is delivered in the future. inspiring feedback and thoughtful commentary to last (See pages 12-13) year’s report. There are more expert insights, observations • INVESTOR LANDSCAPE. Interest in investing and interviews from leading entrepreneurs, investors and in health has gone far beyond the names we have advisors. We added data and content around growth traditionally seen. While pulling together the most areas like digital health, life sciences, digital therapeutics active investors in NYC health, we discovered many and behavioral health. Importantly, in 2020 we saw consumer and tech-focused firms on the list. The 40% growth in both the number of companies thesis is that consumers will drive change and that financed and dollars invested. And for the first time, is borne out by the financing. (See pages 14-15) we are pleased to present the NYC Digital Health 100 – our list of the 100 most promising NYC start-ups. Thank you to all who contributed to this report, and a special acknowledgment to Sanofi, our inaugural sponsor, and to Cooley for their data analysis and ongoing support. As we look ahead to 2020 and beyond, we look forward BUNNY ELLERIN to continued growth, innovation and transformation in President, healthcare in NYC. NYC Health Business Leaders 2 EXPERT INSIGHTS Many Thanks to Our Contributors For our 2020 report, we have assembled an array of esteemed contributors who comprise the who’s who in the NYC healthcare ecosystem — the top entrepreneurs, investors and thought leaders. Sundeep Bhan | Co-Founder & CEO Steve Kraus | Partner PROGNOS BESSEMER VENTURE PARTNERS Nancy Brown | General Partner Ofer Leidner | Co-Founder & President OAK HC/FT HAPPIFY HEALTH Brenton Fargnoli, MD | Partner Hua Lin, PhD | Chief Scientific Officer & ALLEYCORP Co-Founder FORKHEAD BIOTHERAPEUTICS James E. Flynn | Managing Partner DEERFIELD MANAGEMENT Michael Meng | CEO STELLAR HEALTH Jenna Foger | Senior Vice President Science & Technology Emily Minkow | Chief Business Officer ALEXANDRIA VENTURE INVESTMENTS PREVAIL THERAPEUTICS Ron Goldman | Co-Founder Patrick Pilch | Senior Managing Director & KOGNITO National Healthcare Practice Leader BDO Wendy Goldstein | Partner COOLEY Trevor Price | CEO, OXEON HOLDINGS General Partner, TOWN HALL VENTURES Orin Herskowitz | Executive Director COLUMBIA TECHNOLOGY VENTURES Raju Rishi | General Partner RRE VENTURES Trip Hofer | CEO ABLETO Carlo Rizzuto, PhD | Partner VERSANT VENTURES Walter Jin | Chairman & CEO PAGER Brad Svrluga | Co-Founder & General Partner PRIMARY VENTURE PARTNERS Bozidar Jovicevic MD, MBA VP | Global Head of Digital Therapeutics Nina Tandon, PhD | CEO & Co-Founder SANOFI EPIBONE Taylor Justice | Co-Founder & President Chris Wasden | Head of HappifyDTx UNITE US HAPPIFY HEALTH Eric Kinariwala | Founder & CEO Rod Wong, MD | Chief Investment Officer & CAPSULE Managing Partner RTW INVESTMENTS David Benshoof Klein | Co-Founder & CEO CLICK THERAPEUTICS 3 2019 BY THE NUMBERS HEALTH IN FUNDING COMPANIES IN 2019 117 RECEIVED $2.6B FUNDING BY STAGE FUNDING BY SECTOR 5% Seed/Angel % 42 % 30% Life Sciences 6 % Delivery/ Late stage VC 34 Providers Series A 6% % Diagnostics 23% 46 & Devices Series B Digital/ 8% Tech-enabled Other Early stage VC EXITS IPOS Company Acquired by Deal Amount Dassault $5.7 Billion Systèmes Veeva $550 Million Systems $520 Million Lantheus (estimated) YEAR OVER YEAR 2019 2018 Change # Companies Financed 117 83 41% Overall Investment $2.6 Billion $1.85 Billion 41% 4 DIGITAL HEALTH ECOSYSTEM New York State of Mind Over the past ten years, since the inception of NYCHBL, we have seen a dramatic increase in the number of digital health businesses in NYC. Companies like WebMD, Medidata, Crossix, and EverydayHealth NANCY BROWN paved the way for a new generation of startups, General Partner, creating a fertile breeding ground for innovation Oak HC/FT and transformation of the digital health space. Here’s why leading investors and entrepreneurs are bullish THE NUMBER OF TECH-ENABLED on New York’s growth. and digital healthcare companies has exploded. Five years ago, we had just one company in NYC. Now we have at least 6-7 teams with a presence: Galileo, Maven, Quartet, Unite Us to name a few. RAJU RISHI General Partner, RRE Ventures THE ECOSYSTEM HAS EVOLVED SIGNIFICANTLY OVER THE LAST SUNDEEP BHAN DECADE. I started a company in Co-Founder & CEO, 2000 and at that time, Boston and Prognos California were the hubs of startup innovation and VC. Today, NYC is faster I’VE BEEN PART OF THE growing than any other city and we have NYC DIGITAL HEALTH the technical talent to sustain it. ECOSYSTEM for more than 20 years. Prognos is my third company. What’s different today besides the sheer number of start-ups is that larger healthcare companies are more collaborative BRAD SVRLUGA and open to having a dialogue Co-Founder & General Partner, with innovators. Primary Venture Partners BEING IN NYC AND BEING FOCUSED ON NYC makes our lives related to deal flow a lot easier, and it makes us as investors more impactful since we’re not chasing deals in the Bay Area, Austin, Chicago, or anywhere else. Our ability to support entrepreneurs with resources that are generally not more than 20–30 minutes away is a key differentiator. 5 TOP 25 Digital Health Investments in 2019 No. Company Description Funding (MM) Stage Select Investors Rebuilding the pharmacy industry, TCV, Glade Brook Capital, M13, enabling customized outcomes for Late 1 $200 Thrive Capital, University Growth doctors, hospitals, insurers, and stage VC Fund, Oxeon Ventures manufacturers. FirstMark Capital, PROOF Fund, Direct-to-consumer telehealth company Early 2 $85 Evolution VC Partners, TQ Ventures, with brands Roman, Rory and Zero. stage VC Sand Hill Angels, J Ventures Centene, GV, Echo Health Ventures, Improves behavioral health delivery Late 3 $67.5 Polaris Partners, Oak HC/FT, Deerfield for patients, providers, and payers. stage VC Management, F-Prime Capital Provides personalized primary care, Redpoint Ventures, Emblem Health, Early 4 behavioral health care, and social services $65 Thrive Capital, Oxeon Ventures, Town stage VC for underserved urban populations. Hall Ventures, Maverick Ventures Greycroft Partners, Bracket Capital, Provides teeth alignment technology Early 5 $63.4 Bessemer Venture Partners, Riverpark designed to be hassle-free. stage VC Ventures, Fantail Ventures Sequoia, Samsung Venture Direct-to-consumer weight loss and Late Investment, TransLink Capital, 6 $58 exercise tracking mobile applications. stage VC Aglae Ventures, Primary Venture Partners, RRE Ventures Revolution Group, Top Tier Capital Offers affordable and confidential Late Partners, Nomura Capital Partners, 7 online therapy with network of $50 stage VC Spark Capital, Compound, Norwest licensed therapists. Venture Partners Transforming cancer diagnosis, treatment Early Breyer Capital, HealthCare Ventures, 8 $45 and prevention through cutting-edge AI. stage VC Kenan Turnacioglu Harnesses mobile computing and data Early Bayer, Innova Capital Partners, 9 science to transform the lives of people $40 stage VC FJ Labs, RRE Ventures with diabetes. Provides care coordination platform Oak HC/FT, Scout Ventures, Town Hall Early 10 bringing together healthcare and $35 Ventures, Omidyar Network, New York stage VC social services. Ventures, Blossom Street Ventures Polaris Partners, First Round Full-service marketplace for Late Capital, RRE Ventures, 406 11 $34 healthcare jobs. stage VC Ventures, Icon Ventures, Silicon Valley Bank, AlleyCorp 6 EARLY STAGE: Seed/Angel, Series A, Series B LATE STAGE: Series C and beyond No. Company Description Funding (MM) Stage Select Investors Connects patients and consumers Late Ascent Biomedical Ventures, 12 to leading wellness professionals and $31.8 stage VC Northwell Ventures remote monitoring. Dental clinic intended to improve dental Early Redpoint Ventures, Juxtapose, 13 $31.1 visit and entire wellness experience. stage VC Tusk Ventures, Oxeon Ventures McKesson Ventures, Sanofi Real-world evidence and outcomes- Early Ventures, Flare Capital Partners, 14 based analytics solutions for life science $29.4 stage VC Lakestar, Oxeon Ventures, companies and payers. New Enterprise
Load more

Recommended publications
  • RRE VENTURES Technology Venture Capital Since 1994
    RRE VENTURES Technology Venture Capital Since 1994 130 E. 59th St. New York, NY 10022 212.418.5100 | www.rre.com DISTINGUISHING QUALITIES RRE Ventures partners with leading entrepreneurs to build world-class businesses Leading early-stage venture capital firm in NYC Over two decades of top quartile performance $1.6 billion under management 240 companies in 7 funds since inception; 114 active portfolio companies Industry-renowned investment team Unmatched Fortune 100 access to support portfolio companies RRE Ventures | Proprietary and Confidential 2 CORE TEAM • H&Q Venture Capital, JPMorgan, IV Systems, • Brown Brothers Harriman, GateHouse Investors, James D. Robinson GE John R. Hass Cheetah Korea Value Fund Managing Partner • Forbes Midas List 2013 Partner • Princeton AB Politics 1994 2010 • Harvard MBA, Antioch BA Computer Science • Advisory Capital, Morgan Stanley, Dillon Read, • Lerer Ventures, stickybits, The Kraft Group, Massive, Microsoft Stuart J. Ellman McKinsey & Co. Steve Schlafman Managing Partner • Adjunct Professor, Columbia Business School Principal • Northeastern AB Summa Cum Laude, Accounting 1994 • Harvard MBA, Wesleyan BA Economics 2013 & Finance • Former Chairman & CEO – American Express Company • Signia Ventures, Bridgewater Associates, Brookings James D. Robinson III • Ret. Lead Director – Coca-Cola; Ret. Chairman Alice Lloyd George Institution, The Wall Street Journal General Partner • – Bristol-Myers Squibb Associate Princeton AB Public Policy, Minor: East Asian 1994 2014 Studies • Harvard MBA, Georgia Tech BS Industrial
    [Show full text]
  • Private Placement Activity Chris Hastings | [email protected] | 917-621-3750 3/5/2018 – 3/9/2018 (Transactions in Excess of $20 Million)
    Private Capital Group Private Placement Activity Chris Hastings | [email protected] | 917-621-3750 3/5/2018 – 3/9/2018 (Transactions in excess of $20 million) Trends & Commentary ▪ This week, 14 U.S. private placement deals between $20 million and $50 million closed, accounting for U.S. VC Average Deal Size by Series $516 million in total proceeds, compared to last week’s 10 U.S. deals leading to $357 million in total $ in Millions proceeds. This week also had 5 U.S. deals between $50 million and $100 million yielding $320 million, $35 compared to last week’s 4 deals resulting in $279 million in total proceeds. ▪ The U.S. VC average deal size has been significantly increasing for early and late stage VC deals. Late $30 stage VC has increased by 8.8% CAGR 2008 – 2017 while early stage VC has grown by 7.4% CAGR 2008 – 2017. (see figure) ▪ Southern Cross, a PE fund that invests in energy, pharmaceuticals and technology in Latin America, has $25 decided against restructuring its third fund after receiving some interest from its LPs. It is largely because its third fund has been a weak performer, the discount on fund stakes would have been steep and that the $20 fund wanted more time to exit. ▪ Univision has filed to withdraw its pending IPO due to “prevailing market conditions”. Univision initially filed $15 plans to IPO in 2015. ▪ New State Capital Partners has closed its second institutional fund on its $255 million hard cap. The fund $10 can invest more than $50 million equity per deal in sectors such as business services, healthcare services and industrials.
    [Show full text]
  • To Download a PDF of an Interview with James
    PURPOSE Leadership Lessons An Interview with James D. Robinson III, General Partner and Co-Founder, RRE Ventures EDITORS’ NOTE Jim Robinson fascinated by the dynamics of change about it like weeds in the lawn – they come up also sits on the private boards of a and watching the extent to which peo- every day so we have to be on guard to make number of portfolio companies, ple, companies and countries respond sure they don’t strangle what we’re trying to including Avant, CoverHound, to change or fail to respond to change. accomplish. Fast Performance and NerdWallet. Most often, we have a bell-shaped In a smaller company, change sometimes Additionally, he serves as President curve with those that lead change and rears its head in a different fashion. of J. D. Robinson, Inc. He was then we have a bunch in the middle A number of companies, including some Chairman and Chief Executive and then there is the tail that resists we have started, go out to do X and after nine Officer of American Express change until they are irrelevant. months, they fi gure the market isn’t interested Company from 1977 to 1993 The companies we deal with are in X so they change into Y. and Non-Executive Chairman of not all aimed at disrupting, but they’re Then several months later, they fi gure that Bristol-Myers Squibb from 2005 to aimed at the enterprise or network Y isn’t it either but, in the process, they have 2008, where he sat on the board James D.
    [Show full text]
  • FORM 20-F Cootek
    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR _ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report . Commission file number: 001-38665 CooTek (Cayman) Inc. (Exact Name of Registrant as Specified in Its Charter) N/A (Translation of Registrant’s Name Into English) Cayman Islands (Jurisdiction of Incorporation or Organization) Building 7, No. 2007 Hongmei Road, Xuhui District Shanghai, 201103 People’s Republic of China (Address of Principal Executive Offices) Jean Liqin Zhang, Chief Financial Officer Building 7, No. 2007 Hongmei Road, Xuhui District Shanghai, 201103 People’s Republic of China Phone: +86 21 6485-6352 Email: [email protected] (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of Each Class Name of Each Exchange On Which Registered American depositary shares, each representing 50 Class A New York Stock Exchange ordinary share Class A ordinary shares, par value US$0.00001 per share* New York Stock Exchange* *Not for trading, but only in connection with the listing on the New York Stock Exchange of American depositary shares.
    [Show full text]
  • Corporate Venturing Report 2019
    Corporate Venturing 2019 Report SUMMIT@RSM All Rights Reserved. Copyright © 2019. Created by Joshua Eckblad, Academic Researcher at TiSEM in The Netherlands. 2 TABLE OF CONTENTS LEAD AUTHORS 03 Forewords Joshua G. Eckblad 06 All Investors In External Startups [email protected] 21 Corporate VC Investors https://www.corporateventuringresearch.org/ 38 Accelerator Investors CentER PhD Candidate, Department of Management 43 2018 Global Startup Fundraising Survey (Our Results) Tilburg School of Economics and Management (TiSEM) Tilburg University, The Netherlands 56 2019 Global Startup Fundraising Survey (Please Distribute) Dr. Tobias Gutmann [email protected] https://www.corporateventuringresearch.org/ LEGAL DISCLAIMER Post-Doctoral Researcher Dr. Ing. h.c. F. Porsche AG Chair of Strategic Management and Digital Entrepreneurship The information contained herein is for the prospects of specific companies. While HHL Leipzig Graduate School of Management, Germany general guidance on matters of interest, and every attempt has been made to ensure that intended for the personal use of the reader the information contained in this report has only. The analyses and conclusions are been obtained and arranged with due care, Christian Lindener based on publicly available information, Wayra is not responsible for any Pitchbook, CBInsights and information inaccuracies, errors or omissions contained [email protected] provided in the course of recent surveys in or relating to, this information. No Managing Director with a sample of startups and corporate information herein may be replicated Wayra Germany firms. without prior consent by Wayra. Wayra Germany GmbH (“Wayra”) accepts no Wayra Germany GmbH liability for any actions taken as response Kaufingerstraße 15 hereto.
    [Show full text]
  • Masters in Management in Entrepreneurship and New Venture Management
    MASTERS IN MANAGEMENT IN ENTREPRENEURSHIP AND NEW VENTURE MANAGEMENT Research Title: The nexus between entrepreneurship theory and venture capital financing decisions in South Africa Violet S’phiwe Buluma Student Number: 693690 BUSA 7044 Supervisor: Dr Jose Barreira Date of submission: 20 June 2017 ABSTRACT This explorative study examines the decision making criteria at the screening stage by venture capital firms in South Africa. The study also probes into the decision making criteria on the personality side and whether that has any association with the “big five” characteristics. A three- section questionnaire including both Likert style type (decision making and short version of big five) and nominal questions was sent to venture capital firms. Logistic regression as well as correlation analysis was run on the data. The findings were that individual attributes (entrepreneurs’ characteristics and experience) environment, industry and macro economic environment (characteristics of product and services, characteristics of the market and financial considerations) are all positively related to venture capital firms’ decision to grant finance to an entrepreneur. Findings on the big five characteristics are that only openness to experience, consientiousness and extrarversion were seen as critical considerations by venture capital firms, but not agreeableness and emotional stability characteristics. The study findings are beneficial for entrepreneurs and venture capital firms. Key words – Venture capital, investment criteria, big five personality, entrepreneurship, access to finance 2 DECLARATION I Violet S’phiwe Buluma declare that the research work reported in this dissertation is my own, except where otherwise indicated in references and acknowledgements. It is submitted in partial fulfilment of the requirements for the Masters of Management in Entrepreneurship and New Venture Management at the University of the Witwatersrand.
    [Show full text]
  • Click to Edit Master Title Style
    Click to edit Master title style Secondary VIII, L.P. April 14th 2016 Dallas Police & Fire Pension System FirmClick Overviewto edit Master title style Year firm Assets under Number of Number of fund founded management direct investments investments 2000 $2B 175 215 San Francisco Firm Distributions headquarters Number of professionals to Paid-In Capital Firm net IRR 2 offices 17 82%* 21% TWO COMPLEMENTARY FUND STRATEGIES SECONDARY LIQUIDITY PARTNERSHIP HOLDINGS • Secondary direct and secondary fund investments in • Fund and direct investments in early and late-stage venture-backed companies mid-stage venture-backed companies • Typically $20 - $200 million in revenues at time of • Typically pre-revenue to $20 million in investment revenues at time of investment • Seeking high IRR • Seeking high multiple All data is unaudited and estimated as of 9/30/15. *As of 10/21/2015. Aggregate track records are net of fees, expenses and carried interest paid to the general partner entity of each respective fund. Prior performance is not a guarantee 2 of future returns. Please see slide 15 for detailed track record information and a full list of funds. OurClick Team to edit Master title style FIRM MANAGEMENT FINANCE & INVESTOR RELATIONS HANS SWILDENS ROBERT MAY AARON HINZ LENA McNULTY LISA BREIMAN Founder & CEO COO & CCO Controller Investor Relations Investor Relations Speedera, Microline Founders Fund, Mohr Davidow, Thomas Weisel | Venrock Santa Clara University University of Denver UCSB | Columbia MBA Thomas Weisel PricewaterhouseCoopers San Jose State
    [Show full text]
  • Tive, Inc. Form D Filed 2021-06-24
    SECURITIES AND EXCHANGE COMMISSION FORM D Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act. Filing Date: 2021-06-24 SEC Accession No. 0001708414-21-000001 (HTML Version on secdatabase.com) FILER Tive, Inc. Mailing Address Business Address 38 CAMERON AVE 38 CAMERON AVE CIK:1708414| IRS No.: 474350087 | State of Incorp.:DE | Fiscal Year End: 1231 SUITE 200 SUITE 200 Type: D | Act: 33 | File No.: 021-403994 | Film No.: 211039641 CAMBRIDGE MA 02140 CAMBRIDGE MA 02140 5088423439 Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB APPROVAL OMB Number: 3235-0076 Washington, D.C. 20549 June 30, Expires: FORM D 2012 Estimated average burden hours per 4.00 Notice of Exempt Offering of Securities response: 1. Issuer's Identity CIK (Filer ID Number) Previous Name(s) ☒ None Entity Type 0001708414 ☒Corporation Name of Issuer ☐ Limited Partnership Tive, Inc. ☐ Limited Liability Company Jurisdiction of Incorporation/ Organization ☐ General Partnership DELAWARE ☐ Business Trust Year of Incorporation/Organization ☐Other ☒ Over Five Years Ago ☐ Within Last Five Years (Specify Year) ☐ Yet to Be Formed 2. Principal Place of Business and Contact Information Name of Issuer Tive, Inc. Street Address 1 Street Address 2 56 ROLAND STREET SUITE 100A City State/Province/Country ZIP/Postal Code Phone No. of Issuer BOSTON MASSACHUSETTS 02129-1243 617-631-8483 3. Related Persons Last Name First Name Middle Name Komoni Krenar Street Address 1 Street Address 2 c/o Tive, Inc.
    [Show full text]
  • Venture-Capital Syndicates' Collaborative Experience and Start-Up
    Academy of Management Journal The Past Is Prologue? Venture-Capital Syndicates’ Collaborative Experience and Start-Up Exits Journal: Academy of Management Journal Manuscript ID AMJ-2019-1312.R3 Manuscript Type: Revision Financing of new ventures < Entrepreneurship < Topic Areas, Keywords: Interorganizational linkages < Organization and Management Theory < Topic Areas, Network theory < Theoretical Perspectives Past research has produced contradictory insights into how prior collaboration between organizations—their relational embeddedness— impacts collective collaborative performance. We theorize that the effect of relational embeddedness on collaborative success is contingent on the type of success under consideration, and we develop a typology of two kinds of success. We test our hypotheses using data from Crunchbase on a sample of almost 11,000 U.S. start-ups backed by venture-capital (VC) firms, using the VCs’ previous collaborative experience to predict the Abstract: type of success that the start-ups will experience. Our findings indicate that, as prior collaborative experience within a group of VCs increases, a jointly funded start-up is more likely to exit by acquisition (which we call a focused success); with less prior experience among the group of VCs, a jointly funded start-up is more likely to exit by IPO (a broadcast success). Our results deepen understanding of the connections between organizational performance and collaboration networks, contributing to entrepreneurship research on the role of investors in technology ventures. Page 1 of 65 Academy of Management Journal 1 2 3 4 The Past Is Prologue? Venture-Capital Syndicates’ Collaborative 5 Experience and Start-Up Exits 6 7 8 9 10 11 Dan Wang 12 Columbia University 13 [email protected] 14 15 16 Emily Cox Pahnke 17 University of Washington 18 [email protected] 19 20 Rory M.
    [Show full text]
  • NVCA 2021 YEARBOOK Data Provided by Dear Readers
    YEARBOOK Data provided by Credits & Contact National Venture Capital Association NVCA Board of Directors 2020-2021 (NVCA) EXECUTIVE COMMITTEE Washington, DC | San Francisco, CA nvca.org | [email protected] | 202-864-5920 BARRY EGGERS Lightspeed Venture Partners, Venture Forward Chair Washington, DC | San Francisco, CA MICHAEL BROWN Battery Ventures, Chair-Elect ventureforward.org | [email protected] JILL JARRETT Benchmark, Treasurer ANDY SCHWAB 5AM Ventures, Secretary BOBBY FRANKLIN President and CEO PATRICIA NAKACHE Trinity Ventures, At-Large JEFF FARRAH General Counsel EMILY MELTON Threshold Ventures, At-Large JUSTIN FIELD Senior Vice President of Government MOHAMAD MAKHZOUMI NEA, At-Large Affairs MARYAM HAQUE Executive Director, Venture AT-LARGE Forward MICHAEL CHOW Research Director, NVCA and PETER CHUNG Summit Partner Venture Forward DIANE DAYCH Granite Growth Health Partners STEPHANIE VOLK Vice President of Development BYRON DEETER Bessemer Venture Partners RHIANON ANDERSON Programs Director, Venture SCOTT DORSEY High Alpha Forward RYAN DRANT Questa Capital CHARLOTTE SAVERCOOL Senior Director of PATRICK ENRIGHT Longitude Capital Government Affairs STEVE FREDRICK Grotech Ventures MICHELE SOLOMON Director of Administration CHRIS GIRGENTI Pritzker Group Venture Capital DEVIN MILLER Manager of Communications and JOE HOROWITZ Icon Ventures Digital Strategy GEORGE HOYEM In-Q-Tel JASON VITA, Director of Programming and CHARLES HUDSON Precursor Ventures Industry Relations JILL JARRETT Benchmark JONAS MURPHY Manager of Government Affairs
    [Show full text]
  • Analysis of 2014'S Corporate Venture Capital Activity. Released February 2015
    Analysis of 2014’s corporate venture capital activity. Released February 2015 CB Insights is a National Science Foundation-backed company that uses data to provide VCs, corporate strategy, M&A teams and business development professionals with intelligence on emerging companies and disruptive technology trends. To see how our data can make your life easier, visit: www.cbinsights.com 2 3 Corporations making strategic investments in U.S. companies but not as part of a specific separately demarcated venture group are not included. Page 45 details the rules and definitions In 2014, VC funding hit the highest levels since 2000 and we use. corporate VCs played a huge part. Corporate venture capital activity saw a spike in 2014 as deals by corporate venture arms jumped 25% YoY while funding rose 76% behind participation in some of 2014’s largest venture deals ranging from Cloudera to Tango to Slack. Google Ventures led all corporate VCs, investing in 60+% more companies than second place Intel Capital in 2014. Salesforce came in at #3 after a busy 2014, which included investments in Anaplan, Mulesoft, Docusign and others. Average deal size with corporate venture participation reached $23M+ in three of the four quarters in 2014. This was a significant step up from 2013 where average CVC deal sizes Google Ventures and Intel Capital led corporate VCs by number of never topped $17M. U.S.-based exits in 2014, each notching over 3x more exits than third place SR One. In a huge year for healthcare IPOs, four healthcare-focused CVCs made the top 10, all of which counted three or more IPO exits.
    [Show full text]
  • Bloomberg Briefs
    Wednesday June 8, 2016 www.bloombergbriefs.com MedMen Seeks $100 Million for Marijuana Investments QUOTED BY AINSLIE CHANDLER, BLOOMBERG BRIEF Medical cannabis management company MedMen is raising its first institutional fund "This is the toughest decision- as it tries to capitalize on investors' interest in legal marijuana enterprises. making environment that I MedMen is trying to raise $100 million for MedMen Opportunity Fund, according to think we have ever been in.... firm founder and Chief Executive Adam Bierman. Yesterday, JPMorgan comes MedMen, founded in 2009, previously acted as a management company for out and they say there is a 36 businesses with medical marijuana licenses. It also invested money from family offices and venture funds in special purpose vehicles where the investors held the cannabis percent chance of a licenses, Bierman said in a May 26 interview. recession. As a CIO or head Existing investors pushed the firm to raise a fund to allow for greater diversification in of private equity, what do you their portfolios, he said. do with that?" “If you are a multi-billion dollar family office or an institutional quality investor, you are — Glenn Youngkin, President and COO of not making one-off investments in the $3 million to $5 million range with single-asset Carlyle Group, at a conference June 7 exposure in a market that is complicated from a regulatory environment,” Bierman said. The Los Angeles-based firm held a first close on the WEEK IN NUMBERS fund in May and hopes to have a final close within six months, Bierman said. $13.5 billion — Extra return MedMen The fund will invest in cannabis-related projects, he Calstrs calculates it earned from its said.
    [Show full text]